30 June 2022
Business Update, Final Results and Financing Agreement
Shield Provides a Business Update, its Final Results for the Year Ended 31 December 2021 and announces a financing agreement of US$10 million
Shield Therapeutics plc today reports a business update covering recent developments, its audited final results for the year ended 31 December 2021 and details of a financing transaction of US$10 million through a shareholder loan from AOP Orphan International AG (‘AOP’). Upon completion this transaction will extend the Company’s cash runway to approximately the end of calendar 2022.
For full details click here.